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CBackground: To improve comparability of economic data used in de-
cisionmaking, some agencies recommend that a particular instrument
should be used to measure health state utility values (HSUVs) used in
decision-analytic models. The methods used to incorporate HSUVs in
models, however, are often methodologically poor and lack consis-
tency. Inconsistencies in themethodologies usedwill produce discrep-
ancies in results, undermining policy decisions informed by cost per
quality-adjusted life-years. Objective: To provide an overview of the
current evidence base relating to populating decision-analytic models
with HSUVs. Findings: Research exploring suitable methods to accu-
rately reflect the baseline or counterfactual HSUVs in decision-analytic
models is limited, and while one study suggested that general popula-
tion data may be appropriate, guidance in this area is poor. Literature
describing the appropriateness of different methods used to estimate
HSUVs for combined conditions is growing, but there is currently no
consensus on the most appropriate methodology. While exploratory O
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http://dx.doi.org/10.1016/j.jval.2012.05.003nalyses suggest that a statistical regression model might improve ac-
uracy in predicted values, themodels require validation and testing in
xternal data sets. Until additional research has been conducted in this
rea, the current evidence suggests that the multiplicative method is
he most appropriate technique. Uncertainty in the HSUVs used in
ecision-analytic models is rarely fully characterized in decision-ana-
ytic models and is generally poorly reported. Conclusions: A substan-
ial volume of research is required before definitive detailed evidence-
ased practical advice can be provided. As themethodologies used can
ake a substantial difference to the results generated from decision-
nalytic models, the differences and lack of clarity and guidance will
ontinue to lead to inconsistencies in policy decision making.
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opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
To facilitate comparison of results from decision-analytic models,
there has been a move toward policy decision-making bodies pro-
posing a specificpreference-basedmeasure suchas the EuroQol five-
dimensional (EQ-5D) questionnaire [1,2]. Inconsistencies in the way
the health state utility values (HSUVs) are usedwill produce discrep-
ancies in the results generated, which will undermine policy deci-
sions informedbycost perquality-adjusted life-years (QALYs).While
literature describing best practice in decision-analytic modeling is
available [2–4], research exploring the practical issues arising when
applying preference-based HSUVs in these models is scarce.
This article provides an overview of the current evidence base
relating to issues involved in populating decision-analytic models
[5]. Specifically,we look at 1) suitableHSUVs for the baseline/coun-
terfactual health states (see definition below), 2) appropriate
methods when combining or adjusting HSUVs for multiple health
conditions/comorbidities (where an additional condition coexists
alongside the primary condition), and 3) issues when characteriz-
This article is based on a technical support document that wa
through its Decision Support Unit. The views, and any errors or om
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Published by Elsevier Inc.ing uncertainty in HSUVs. We provide practical advice where pos-
sible and highlight where additional research is warranted. While
the issues covered in this article are particularly relevant to ana-
lysts populating decision-analytic models using summary statis-
tics reported in the literature, many are also relevant to analysts
who have access to patient-level data.
Baseline/Counterfactual HSUVs
Decision-analytic models submitted to reimbursement authorities
generally assess the benefits of interventions in termsof their poten-
tial to avoid or alleviate a clinical event or condition. As a conse-
quence, in addition to theHSUVs associatedwith the event and con-
dition, analysts need to know the HSUVs associated with not
experiencing theeventor thehealthcondition, that is, thebaselineor
counterfactual values. For example, in patients with a history of car-
diovascular disease (CVD), to assess the benefits of avoiding a stroke,
analystsneed theaverageHSUV for a cohortwhohaveexperienceda
stroke and the average HSUV for a cohort who have not experienced
ded by the National Institute for Health and Clinical Excellence
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972 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 7 1 – 9 7 4a stroke but have a history of CVD (i.e., the baseline). Similarly, when
assessing the potential benefits of a screening program for colorectal
cancer, analysts need the average HSUV from a cohort who have
colorectal cancer and the average HSUV from a cohort who do not
have colorectal cancer (i.e., the baseline).
Evidence that can be used to represent the condition-specific
baseline is often limited, and while some analysts have assumed
that the alleviation of a health conditionwill return health-related
quality of life (HRQOL) to full health (i.e., a health utility value of 1)
[6], this approach is flawed. Using the previous examples, if a
stroke is avoided, there will still be a detrimental effect on HRQOL
due to CVD. Similarly, if bowel cancer is prevented, the average
patient could still have at least one prevalent health condition that
has a detrimental effect on HRQOL. It has been shown that the
costs per QALY results generated when using different baseline
HSUVs in the same model differ to such an extent that they could
influence a policy decision based on a cost per QALY threshold [7].
Many decision models use lifetime horizons to accrue QALY
gains, and the average baseline will not be constant across the full
horizon modeled due to the increasing prevalence of comorbidi-
ties in older-aged cohorts and the detrimental effect on HRQOL
associated with age [8]. It has been suggested that average HSUVs
from the general population could be used as the baseline when
condition-specific data are not available [9]. Because HSUVs ob-
tained from the general population are informed by subgroups
with many different conditions, intuitively this makes sense for
less prevalent health conditions, or conditions that do not have a
substantial effect on HRQOL, because removing a particular sub-
group of people who have one of the conditions will not have a
substantial effect on the average HSUVs.
Authors of a recent study examined themean EQ-5D question-
naire scores for subgroups of respondents (n 41,174) classified by
self-reported health condition in theHealth Survey for England [8].
The objective was to determine whether data from the general
population could be used as proxy scores for the baseline (i.e., the
HRQOL associated with not having the particular condition) in
models. The appropriateness of the general population data was
assessed by comparing the age-stratified mean EQ-5D question-
naire scores from respondents without a specific condition with
matched subgroups from the general population. The study pres-
ents a number of age-stratified EQ-5D questionnaire scores cate-
gorized by broadly defined health conditions such as cardiovascu-
lar conditions, or arthritis/rheumatism or fibromyalgia. The
authors reported that while data from the general population
could potentially be used as proxy scores for some conditions,
they may not be appropriate for all, and for some conditions, it
may be more appropriate to use data from respondents who have
none of the prevalent health conditions. If condition-specific data
are not available, they suggest that a range of sensitivity analyses
should be generated, with data from the general population used
as one end of a range of plausible values.
Combining/Adjusting HSUVs
Health care decision-analytic models describe the clinical path-
way followed by typical patients and can involve multiple health
states representing the primary health condition, with additional
health states representing comorbidities (where an additional
condition coexists alongside the primary condition). An example
might be when assessing the cost-effectiveness of statin treat-
ment (which has the potential to reduce the risk of cardiovascular
conditions) in patients with rheumatoid arthritis (RA) [10]. This
cost-effectiveness model includes health states defined as RA but
no history of CVD, RA and heart attack, or RA and stroke. Each of
the individual health states in a decision-analytic model require
HSUVs derived from patients whose health condition(s) mirrors
the health state definitions in the model. Ideally, these would be sobtained from cohorts with the conditionsmodeled, and it is often
possible to derive the required utilities from existing catalogs in-
formed by a comprehensive data set and appropriately classified
conditions [11]. These utility values would be preferable to estimat-
ing values by using data collected from cohorts in disparate studies
or subgroupswithsingle conditions.However, becauseof thevolume
of different combinations of health states and conditions, the exact
data required are not always available, and in these instances the
mean HSUVs for the combined health states are frequently esti-
mated by using the mean HSUVs obtained from patients with the
single conditions [12]. There is currently no consensus onwhich par-
ticular method is preferred to estimate these HSUVs, and the ap-
proaches used can produce very different estimates [13,14].
The threemethods typically used to estimate amean HSUV for a
combined condition when data are available only for relevant single
conditions are the additive, multiplicative, or minimum methods.
These assign a constant absolute decrement, a constant relative dec-
rement, andno additional decrement over that observed for the con-
dition with the lowest HSUV, respectively. A variation of the mini-
mum method (the adjusted decrement estimator) has been
suggested, and linear models incorporating terms to represent the
three traditional methods (additive, multiplicative, and minimum)
and obtained using ordinary least square regressions have been pre-
sented [12,15–17]. Specific details of the five methods are provided
online.
A review of the literature in this area was conducted with arti-
cles identified by a systematic search of CINAHL, the Cochrane
library, EMBASE, MEDLINE, PsycInfo, and Web of Science (1950–
February 2012). The search combined terms for HRQOL (health
state utility, quality of life, Euroqol, EQ5D, health utilities mark,
HUI, short form six D, SF-6D, SF6D),methodologies (standard gam-
ble, SG, time trade off, TTO, additive, multiplicative, minimum,
regression, model), and terms for joint health states (joint health
state, comorbid, combined health states, concurrent, multiple).
This was supplemented by a forward and backward citations
search in the Web of Knowledge and Google Scholar databases.
The objective was to conduct a detailed critical review of existing
empirical literature to gain an understanding of the reasons for
differences in results and conclusions. Studieswere included in the
review if they estimated HSUVs for joint health conditions by using
HSUVs fromsingle conditions. Eleven studies that reported results of
analyses exploring the accuracy of and/or comparing the perfor-
mance of themethodsused to estimatemeanHSUVswere identified
[13].Onearticlewasexcludedbecause itwasaneditorial informedby
the results of one of the articles included in the review [18]. A second
studywasused to informthediscussion, but itwasexcludedbecause
it reviewed the results of the early publications identified in the
search but had not had access to the later publications [14].
Three of the 11 studies included used individual-level patient
data (n 50–207) directly elicited by using either standard gamble
or time trade-off [16,19,20]. The remaining eight used HSUVs ob-
tained by using generic questionnaires (EQ-5D questionnaire  4
[15,17,21,22], six-dimensional health state short form [derived
from short form 36 health survey]  3 [12,23,24], health utilities
index 3  1 [25]) collected during surveys (range 5,224–131,535
espondents). Two of the studies evaluated just one method, and
he others compared results generated by using two, three, or
ore methods. The authors of the review reported that the range
f actual utilities estimated influenced the accuracy of the meth-
ds and thus analysts’ conclusions. For example, although the
inimum outperformed the additive and multiplicative methods
n one study [22], the data estimated covered a very narrow range
0.611–0.742) and two of the other studies demonstrated that the
agnitude of the errors for the minimum method increased sub-
tantially when estimating lower utility values [12,17]; thus, the
ndings of the first study cannot be generalized beyond their data
et without additional research. On a similar theme, the authors
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973V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 7 1 – 9 7 4noted that the use of mean errors when comparing methods was
insufficient because these masked bias in the errors [12,17].
Finally, the accuracy of the method used was influenced by the
value assigned to normal health, and the errors in estimated val-
ues increased when full health (EQ-5D questionnaire  1) was
used to determine the decrement associated with the single
health conditions. The uncertainty in the estimated HSUVs has
not been studied, and there is very little evidence describing re-
sults when estimating HSUVs for more than two simultaneous
conditions. The authors of the review concluded that while there
is currently no unequivocal evidence, the linear models obtained
by using ordinary least square regressions outperformed the other
methods. Because these models require validation in external
data, and each quality-of-life instrument and set of preference
weights would require a unique statistical model, on the basis of
current evidence, however, the authors recommend the multipli-
cative method. We concur with this recommendation at this time
but appreciate that the use of statistical models could be more
appropriate once this research has been developed and validated.
Adverse events
When considering the inclusion of adverse events associated with
a treatment or intervention (e.g., nausea is a side effect of treat-
ment given for influenza) in decision-analytic models, it is essen-
tial to differentiate between acute events and chronic sequelae,
and the inclusion of decrements onHRQOL associatedwith grades
3 to 4 (severe with marked limitation in activity—life threatening/
disabling, requiring medical intervention) adverse events is par-
ticularly relevant [26]. Conversely, applying decrements for grades
1 to 2 (mild or transient discomfort—moderate limitation in activ-
ity, requiring no or minimal medical intervention) adverse events
can introduce an element of double counting because the average
HSUVs obtained from the main cohort are likely to include the
disutility associated with these events.
A review commissioned by the National Institute for Health
Research Health Technology Assessment program examined cur-
rent practice when incorporating adverse events in economic
models described in Health Technology Assessment reports pub-
lished between 2004 and 2007 [27]. Forty-seven of the 80 studies
reviewed were assessments conducted to inform National Insti-
tute for Health and Clinical Excellence appraisals. The authors
recommended that a clear justification should be provided for the
noninclusion of adverse effects together with an explicit report of
howadverse effects are considered in the decision-analyticmodel.
They suggested that systematic searches are required to identify
the HSUVs required for adverse events and recommended re-
search exploring the best approach to ensure that any adverse
effects of interventions are captured.
Authors of a recent cross-sectional review of HRQOL data used
in Health Technology Appraisals (n  46) submitted to National
nstitute for Health and Clinical Excellence during the period 2004
o 2008 reported a wide range of methodological variation in the
se of utility values and a lack of clarity in the reporting of detailed
ethods used in the submissions [28]. They found that adjust-
ents for adverse events were made by either adding or subtract-
ng a value (72%) from the original HSUVs, multiplying by a weight
18%), or incorporating a multivariate analysis (10%). Again, they
oncluded that further guidance is required to clarify the appro-
riateness of adjusting values and the preferred methods for un-
ertaking these adjustments.
Capturing Uncertainty in HSUVs
Decision-analytic models in health care combine evidence from a
range of sources and frequently extrapolate both costs and effects
over time and between patient groups and settings. It is now stan- rdard practice to perform full probabilistic sensitivity analyses by
using Monte-Carlo simulations to explore the uncertainty of input
parameters [29]. The parameter uncertainty indicates the impreci-
sion in the cost-effectiveness results and is used to inform the deci-
sion uncertainty through cost-effectiveness acceptability curves
[30,31]. Ideally, each point estimate includedwithin themodel is de-
scribed by a full probability distribution that reflects the uncertainty
surrounding the value accurately [32,33]. The distributions used to
describe the uncertainty are not selected arbitrarily but are informed
by thedata, the typeof parameter, and theestimationprocess.While
there is a wealth of literature describing appropriate methods for
handling skewed cost data [34], little attention has been paid to the
methods used to capture the uncertainty in HSUVs.
It has been reported that uncertainty around HSUVs is usually
underreported and that frequently only mean values are used in
decision-analytic models [35]. HRQOL data, and in particular the
EQ-5D questionnaire, are not normally distributed. They are
bounded by the limits of the index, often involve negative values,
and are typically skewed, bimodal, or trimodal [36]. Nevertheless,
the uncertainty in the mean can be adequately described by sam-
pling from a normal distribution in themajority of cases. Exceptions
includewhensampling for apatient-level simulationmodel byusing
data that has a relatively low or high mean score and a wide distri-
bution. In these cases, an alternative approach would be to describe
the utility values as decrements [37] characterized by using a log
normal or gammadistribution thatwould give a sampled utility dec-
rement on the interval (0, positive infinity). If a lower constraint is
required (e.g., 0.594 for the UK EQ-5D questionnaire index), the
standard beta distribution could be scaled upward by using a height
parameter () producing a distribution on a (0, ) scale.
An additional source of uncertainty, which is typically ignored,
relates to the preference-based weights. Instruments such as the
six-dimensional health state short form (derived from short form
36 health survey), health utilities index 3, and EQ-5D question-
naire include a number of questions relating to the respondent’s
health. The EQ-5D questionnaire, for example, has five questions
with three possible responses to each. This gives a total of 243 (35)
distinct health states. Because it is not practical to value all possi-
ble health states, a selection is typically valued. The statistical
regression models fitted to the health states valued will consist of
one ormore parameter estimates (the preferenceweights) that are
estimated with uncertainty. Although there is no reason, this
source of uncertainty is typically ignored in decision-analytic
models.When using patient-level data or when performing “map-
ping” exercises, it is simple to reflect this uncertainty by propagat-
ing the uncertainty and associated correlations in the covariance
matrix in the probabilistic sensitivity analysis (see Appendix in
upplemental Materials found at http://dx.doi.org/10.1016/j.jval.
012.05.003for link to EQ-5D questionnaire matrix). In addition,
hen the required preference-based data are not available, these
ata can be estimated by usingmapping functions generated from
RQOL or clinical variables [1,38]. While there is a growing evi-
ence base providing statistical regression models that can be
sed to estimate the required preference-based data [39], very few
uthors provide the statistics required to incorporate uncertainty
n probabilistic analyses. These are both sources of uncertainty
hat are relevant to decision makers and ought to be reflected in
he analysis of uncertainty in the same way as other sources of
arameter uncertainty.
Decision-analytic models generally incorporate multiple
ealth states describing changes in the health condition (e.g., dis-
ase progression, adverse events, and distinct events such as
eart attacks and strokes) that may require unique HSUVs. Corre-
ations between these HSUVs should be characterized in the prob-
bilistic sensitivity analyses using multivariate distributions. Al-
ernative approaches are currently being explored, and the
esulting recommendationswill be a useful reference for analysts.
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974 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 7 1 – 9 7 4In addition, a recent publication suggests that the standard error
of measurement for a number of leading health utilities varies
dependingwhere along the health continuum themeasurement is
made [40]. These last two are examples of the growing volume of
work in this area, and the literature should be continually re-
viewed to take account of emerging evidence.
Discussion
Robust research in this area is scarce, but it is clear that the meth-
odologies employed when using HSUVs in decision-analytic mod-
els can make a substantial difference to the results generated and
the differences in the methodologies will lead to inconsistent pol-
icy decision making [7]. One theme that was apparent throughout
he evidence reviewed to inform this article was a lack of clarity
nd transparency in reports describing the methodologies used
hen applying HSUVs in decision-analytic models.
A substantial volume of research is required before definitive
etailed evidence-based practical advice can be provided in this
rea including longitudinal data describing potential changes in
SUVs for subgroups of patients with specific health conditions,
nalyses exploring appropriate baseline data for the counterfac-
ual health states in decision-analytic models to enable more pre-
ise calculations of the incremental heath benefits of treatment,
mpirical research on the most appropriate method for adjusting
ata to reflect comorbidities and/or adverse events, primary stud-
es collecting data for acute events, and research to determine the
lass/type and duration of adverse event that should be incorpo-
ated in economic models.
Source of financial support: National Institute for Health and
linical Excellence.
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